Zusammenfassung
Die Einführung der Anticoagulantientherapie mit Heparin- und Cumarin-derivaten bedeutete zweifellos einen wesentlichen Fortschritt im Kampf gegen Thrombose und Embolie. Entsprechend ihrem Wirkungsmechanismus liegt das Schwergewicht dieser Pharmaka in der Prophylaxe thrombo-embolischer Komplikationen; ein schon bestehender Thrombus kann damit höchstens am Weiterwachsen verhindert, nicht aber wieder aufgelöst werden. Von manchen Autoren [HALSE, HALSE et al., SANDRITTER et al. (1954, 1958)] wird zwar eine thrombolytische Wirkung angenommen, ist jedoch keineswegs allgemein anerkannt. Es blieb somit der Wunsch nach einer Behandlung, welche die Thrombose wirklich zum Verschwinden bringen konnte, bestehen.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Abe, T.: Reaction mechanism between epsilon-aminocaproic acid on fibrinolysis. Proc. 7th Congr. Europ. Soc. Haem. London, 1959, 2, 919 (1960).
Ablondi, F. B., J. J. Hagan, M. Philips, and E. C. de Renzo: Inhibition of plasmin, trypsin and the streptokinase-activated fibrinolytic system by epsilon-amino-caproic acid. Arch. Biochem. 82, 153 (1959).
Ablondi, F. B., J. J. Hagan, M. Philips, and E. C. de Renzo: Mechanism of clot lysis by streptokinase and effects of epsilon-aminocaproic acid. Proc. Soc. exp. Biol. (N. Y.) 102, 717 (1959).
Albrechtsen, O.K.: The fibrinolytic activity of human tissues. Brit. J. Haematol. 3, 284 (1957).
Alkjaersig, N.: The activation of plasminogen in vitro and in vivo. In: International Symposium on Anticoagulants and Fibrinolysins. Philadelphia: Lea and Febiger 1961a.
Alkjaersig, N. The antifibrinolytic activity of platelets. In: Blood platelets. In: Henry Ford Hospital International Symposium. Boston: Little, Brown and Co. 1961b.
Alkjaersig, N., A. P. Fletcher, and S. Sherry: Epsilon-amino-caproic acid an inhibitor of plasminogen activation. J. biol. Chem. 234, 832 (1959).
Alkjaersig, N., A. P. Fletcher, and S. Sherry The mechanism of clot dissolution by plasmin. J. clin. Invest. 38, 1086 (1959).
Alkjaersig, N., A. P. Fletcher, and S. Sherry Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (“fibrinolytic”) states. II. The significance, mechanism and consequences of defective fibrin polymerization. J. clin. Invest. 41, 917 (19
Ambrus, C. M., N. Back, and J. L. Ambrus: On the mechanism of thrombolysis by plasmin. Circulat. Res. 5, 161 (1962).
Ambrus, C. M., N. Back, and G. Markus: Plasmin-antiplasmin complex as a reservoir of fibrinolytic enzyme. Amer. J. Physiol. 199, 491 (1960).
Ambrus, J. L., C. M. Ambrus, N. Back, J. E. Sokal, and G. L. Collins: Clinical and experimental studies on fibrinolytic enzymes. Ann. N. Y. Acad. Sci. 68, 97 (1957).
Ambrus, J. L., C. M. Ambrus, J. E. Sokal, G. Markus, N. Back, L. Stutzman, D. Razis, C. A. Ross, B. H. Smith, A. C. Rekate, C. L. Collins, D. L. Kline, and J. B. Fishman: Clinical pharmacology of various types of fibrinolytic enzyme preparations. Amer. J. Cardiol. 6, 462 (1960).
Amery, A., H. Maes, J. Vermylen, and M. Verstraete: The streptokinase reactivity test (SKRT). Thrombos. Diathes. haemorrh. (Stuttg.) 9, 175 (1963).
Amery, A., H. Maes, J. Vermylen, H. Maes M. Verstraete: Influence d’un dérivé du niacin sur le système fibrinolytique de l’homme. I. Apposition de l’activité fibrinolytique après différents modes d’administration. N. R. F. Hémat. 2, 70 (1962).
Amris, C. J., V. Larse, and B. Mogensen: Infusin of porcine plasmin in man. Scand. J. clin. Lab. Invest. 15, 179 (1963).
Anlyan, W., G. D. Silver, H. L. Deaton, L. Fort, and J. L. Webster: Fibrinolytic agents in surgical practice. J. Amer. med. Ass. 175, 290 (1961).
Astrup, T.: The biological significance of fibrinolysis. Lancet 1956 II, 565.
Astrup, T. Fibrinolysis in the organism. Blood 11, 781 (1956b).
Astrup, T., O. K. Albrechtsen, M. Claessen, and J. Rasmussen: Thromboplastic and fibrinolytic activity of the human aorta. Circulat. Res. 7, 969 (1959).
Astrup, T., O. K. Albrechtsen, M. Claessen, and S. Müllertz: The fibrin plate method for estimating fibrinolytic activitv. Arch. Biochem. 40, 346 (1952).
Astrup, T., O. K. Albrechtsen, M. Claessen, and P. M. Permtn: Fibrinolysis in the animal organism. Nature (Lond.) 159, 681 (1947).
Astrup, T., O. K. Albrechtsen, M. Claessen, and A. Stage: Isolation of a soluble fibrinolytic activator from animal tissue: Nature (Lond.) 170, 919 (1952).
Astrup, T., and J. Sterndorff: A fibrinolytic system in human milk. Proe. Soc. exp. Biol. (N. Y.) 84, 605 (1953).
Astrup, T., and J. Sterndorff The plasminogen activator in animal tissue. Acta physiol. scand. 36, 250 (1956).
Back, N., J. L. Ambrus, J. W. Byron, and S. Shulman: Effect of delayed treatment with plasmin (fibrinolysin) on thrombi produced with J131-labelled fibrinogen. Fed. Proc. 15, 396 (1956).
Back, N., J. L. Ambrus, J. W. Byron C. L. Simpson, and S. Shulman: Study on the effect of streptokinase-activated plasmin (fibrinolysin) on clots in various stages of organization. J. clin. Invest. 37, 864 (1958).
Bang, N. U., A. P. Fletcher, N. Alkjaersig, and S. Sherry: Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (“fibrinolytic”) states. III. Demonstration of abnormal clot structure by electron microscopy. J. clin. Invest. 41, 935 (1962).
Baumgarten, W., and R. Cole: Human plasminogen-streptokinase complex. The question of the existence of a separate activator entity. Thrombos. Diathes. haemorrh. (Stuttg.) 5, 605 (1961).
Beck, E., R. Schmutzler, and F. Duckert: Inhibition of fibrinolysis and fibrinogenolysis in man: Comparison of epsilon-aminocaproic acid and kallikrein inhibitor: Thromb. Diathes. haemorrh. (Stuttg.) 10, 106 (1963).
Beller, F. K., U. W. Nagel: Thrombolyse: Eine neue Therapie thromboembolischer Erkrankungen. Med. Welt 36, 1863 und 37, 1928 (1960).
Bjerrehuus, J.: Fibrinolytic activity of urine. Scand. J. clin. Lab. Invest. 4, 179 (1952).
Böszörmenyi, J.: Simplified method for the routine determination of antistreptokinase titer. Z. Immun.-Forsch. 124, 411 (1962).
Bougek, R. J., and W. B. Murphy: Segmental perfusion of the coronary arteries with fibrinolysin in man following a myocardial infarction. Amer. J. Cardiol. 6, 525 (1960).
Bouvier, C. A., P. Ruegsegger J. Nydeck: Etude histologique de l’effect d’enzymes fibrinolytiques sur l’évolution d’un infarctus expérimental chez le chien. Helv. med. Acta 27, 656 (1960).
Boyles, P. W.: A method for the induction of segmental radio-opaque blood clots. Amer. J. clin. Path. 30, 423 (1958).
Boyles, P. W. Experimental evaluation of fibrinolytic enzymes. Conference on Thrombolytic Agents, p. 170, Chicago, 1960.
Boyles, P. W. Laboratory procedures and therapy in coronary thrombosis. J. Amer. med. Ass. 175, 279 (1961).
Boyles, P. W., W. H. Meyer, J. Graff, C. C. Ashley, and R. G. Ripic: Comparative effectiveness of intravenous and intra-arterial fibrinolysin therapy. Amer. J. Cardiol. 6, 439 (1960).
Cathie, J. A. B., and J. C. W. Macfarlane: Adjuvants to streptomycin in treating tuberculous meningitis in children. Lancet II 1950, 784.
Christensen, L. R.: Streptococcal fibrinolysis: A proteolytic reaction due to a serum enzyme activated by streptococcal fibrinolysin. J. gen. Physiol. 28, 363 (1945).
Clarke, R. L., and E. E. Cliffton: The treatment of cerebrovascular thromboses and embolism with fibrinolytic agents. Amer. J. Cardiol. 6, 546 (1960).
Cllffton, E. E.: The present status of therapeutic use of enzymes. Amer. J. med. Sci. 228, 568 (1954).
Clarke, R. L., and E. E. Cliffton: The use of plasmin in humans. Ann. N. Y. Acad. Sci. 68, 209 (1957).
Clarke, R. L., and E. E. Cliffton: Early experience with fibrinolysin. Angiology 10, 244 (1959).
Clarke, R. L., and E. E. Cliffton: Review of clinical experience with clot-lysing agents. Amer. J. Cardiol. 6, 496 (1960).
Clarke, R. L., and E. E. Cliffton: The present status of fibrinolytic therapy. Angiology 11, 533 (1963).
Clarke, R. L., and G. R. Downie: Variations in proteolytic activity of serum of animals including man. Proc. Soc. exp. Biol. (N. Y.) 73, 559 (1950).
Clarke, R. L., and G. R. Downie C. E. Gross, and D. Cannamela: Lysis of thrombi produced by sodium morrhuate in the femoral vein of dogs by human plasmin (fibrinolysin). Ann. Surg. 139, 52 (1954).
Coats, G., Seitz, R.: Probleme der sogenannten Netzhautvenenthrombose. Wien. med. Wschr. 8, 180 (1963).
Connell, J.F., and L.M. Rousselot: The use of enzymatic agents in the debridement of burn and wound sloughs. Surgery 30, 43 (1951).
Courbier, R., J. Torresani, J. R. Monties, Y. Patrice, J. Figarella B. Garabedian: Traitement de l’embolie pulmonaire par la fibrinolysine, Recherches expérimentales. Ann. Chir. 16, 231 (1962).
Dastre, A.: Fibrinolyse dans le sang. Arch. int. phys. norm. path. (Paris) 5, 611 (1893).
Davis, N. D., B. J. Carroll, and S. H. Schwartz: Treatment of thrombophlebitis with a fibrinolytic agent (with special references to side effects). Amer. J. Cardiol. 6, 513 (1960).
Denis, P. S.: Essai sur l’application de la chimie à l’étude physiologique du sang de l’homme et à l’étude physio-pathologique, hygiénique et thérapeutique des maladies de cette humeur. Paris: Béchet jre. 1838.
Denny-Brown, C.: Pathophysiology, in cerebral vascular diseases. Third Conference. New York-London: Grune & Stratton 1961.
Denys, J., et H. De Marbaix: Les peptonisations provoquées par le chloroforme. Cellule 5, 197 (1
Deutsch, E.: Derzeitiger Stand der Fibrinolyse. In: M. Ratschow, A. Haltern U. D. Haan: Fortschritte der Angiologie. Darmstadt: Steinkopff-Verlag 1963.
Deutsch, E. P. Elsner U. A. Kratochwil: Über die Wirkung bakterieller Pyrogene unter besonderer Berücksichtigung der Fibrinolyse. Wien. klin. Wschr. 71, 586 (1959a).
Deutsch, E. P. Elsner U. A. J. Marschner: The mechanism of fibrinolysis induced by bacterial pyrogens. Thrombos. Diathes. haemorrh. (Stuttg.) 3, 286 (1959 b).
Deutsch, E. P. Elsner, U. M. Fischer: Die Wirkung intravenös applizierter Streptokinase auf Fibrinolyse und Blutgerinnung. Thrombos. Diathes. haemorrh. (Stuttg.) 4, 482 (1960).
Dewar, H. A., A. R. Morler, and A. J. Cassells-Smith: Fibrinolytic treatment of coronary thrombosis. Brit. med. J. II 1961, 671.
Donaldson, V. H.: Effect of plasmin in vitro on the clotting factors in plasma. J. Lab. clin. Med. 56, 644 (1960).
Drance, S. M.: An ophthalmologist’s approach to fibrinolysis. Angiology 12, 149 (1961).
Duckert, F.: Mécanisme de la coagulation. Röntgen-U. Lab.-Prax. 9, 156; 11, 203; 12, 224 (1960).
Engler, H. S., P. Christopher, and W. H. Moretz: The use of fibrinolysin in the prevention of thrombus formation in small artery anastomoses. Angiology 10, 259 (1959).
Engler, H., W. Headley, L. R. Clough, and H. W. Moretz: The effect of fibrinolysin on the incidence of thrombosis in small artery suturing. Angiology 12, 152 (1961).
Evans, J. A.: Treatment of acute thrombophlebitis of the arm after radical mastectomy. Angiology 12, 155 (1961).
Fischbacher, W.: Beitrag zur Fibrinolyse. Inaug.-Diss. Zürich 1960.
Fischbacher, W. Beitrag zur fibrinolytischen Therapie mit Streptokinase und Fibrinolysin. Thrombos. Diathes. haemorrh. (Stuttg.) 6, 547 (1961).
Fletcher, A. P., N. Alkjaersig, W. D. Sawyer, and S. Sherry: Evaluation of human fibrinolysin (Actase). Lack of fibrinolytic activity after intravenous administration in man. J. Amer. med. Ass. 172, 912 (1960).
Fletcher, A. P., N. Alkjaersig, W. D. Sawyer, and S. Sherry: The assay of thrombolytic (“fibrinolytic”) mixtures intended for therapeutic use. J. Lab. clin. Med. 57, 620 (1961).
Fletcher, A. P., N. Alkjaersig, W. D. Sawyer, and S. Sherry Fibrinolytic mechanism and the development of thrombolytic therapy. Amer. J. Med. 88, 738 (1962a).
Fletcher, A. P., N. Alkjaersig, W. D. Sawyer Influence of clot composition on thrombolysis in plasma. Fed. Proc. 21, 63 (1962
Fletcher, A. P., N., and A. J. Johnson: Methods employed for purification of streptokinase. Proc. Soc. exp. Biol. (N. Y.) 94, 233 (1957).
Fletcher, A. P., N., and S. Sherry: The maintenance of a sustained thrombolytic state in man. I. Induction and effects. J. clin. Invest. 88, 1096 (1959a).
Fletcher, A. P., N. S. Sherry, N. Alkjaersig, F. E. Smyrniotis, and S. Jick: The maintenance of a sustained thrombolytic state in man. II. Clinical observations on patients with myocardial infarction and other thromboembolic disorders. J. clin. Invest. 38, 1111 (1959 b).
Freimann, A., N. U. Bang, C. E. Gross, and E. E. Cliffton: Factors affecting the formation and dissolution of experimental thrombi. Amer. J. Cardiol. 6, 426 (1960).
Friedman, M. W.: Streptokinase in ophthalmology. Amer. J. Ophthal. 35, 1184 (1952).
Fukuttake, K., K. Shida, T. Araeawa, and K. Kato: Analysis of fibrinolysis by the use of epsilon-aminocaproic acid: Preliminary report. Blood 15, 690 (1960).
Fürstenberg, H. S.: Fibrinolyse in der Urologie. Intern. Kongr. Chir., Amsterdam 1962.
Giacomazzi, G.: Influence de l’héparine sur la fibrinolyse activée par la streptokinase. Sang 29, 614 (1938).
Goossens, N.: Erfahrungen bei obliterierenden Arteriopathien. Thrombos. Diathes. haemorrh. (Stuttg.) VII, (1963) Suppl. 3, p. 203.
Gross, R.: Erfahrungen der intravenösen Anwendung von hochgereinigter Streptokinase. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 3 ad VII, 153 (1963 a).
Gross, R. Findings with labeled streptokinase in vivo and in vitro. IX. Congr. Soc. Europ. hemat. Lissabon (1963b).
Gross, R. W. Hartl, G. Kloss U. B. Rahn: Thrombolyse durch Infusionen hochgereinigter Streptokinase. Dtsch. med. Wschr. 49, 2129 (1960).
Grossi, G. E., and E. E. Cliffton: The lysis of arterial thrombi in rabbits and dogs by use of activated human plasminogen (fibrinolysin) (plasmin) Surgery 37, 794 (1955).
Grossi, G. E., and E. E. Cliffton Clinical use of human fibrinolysin and streptokinase in thromboembolic diseases. Conference on thrombolytic Agents, Chicago, 1960, S. 222.
Grossi, G. E., and E. E. Cliffton, and D. A. Cannamela: The lysis of intravascular thrombi in rabbits with human plasmin (fibrinolysin) Blood 9, 310 (1954).
Halse, TH.: Das fibrinolytische Potential. Medizinische 1958, 2044 und 2102.
Halse, TH Enzymologie der spontanen und therapeutisch induzierten Fibrinolyse. Z. Vitamin-,Hormon-U. Fermentforsch. 11, 1 (1960).
Halse, TH., K. Philipp U. F. Ruf: Tierexperimentelle Untersuchung über intravasale Thrombolyse mit Heparin und Thrombacid. Langenbecks Arch. Hin. Chir. 263, 459 (1950).
Harms, CL., Seitz, R.: Probleme der sogenannten Netzhautvenenthrombose. Wien. med. Wschr. 8, 180 (1963).
Hartert, H.: Die Thrombelastographie. Eine Methode zur physikalischen Analyse der Blutgerinnungsvorgänge. Z. ges. exp. Med. 117, 189 (1951).
Hartert, H. Klinische Blutgerinnungsstudien mit der Thrombelastographie. I. Dtsch. Arch. klin. Med. 199, 234 (1952).
Hecker, S. P., and H. C. Zweng: Central retinal artery occlusion successfully treated with plasmin. J. Amer. med. Ass. 176, 1067 (1961).
Heimburger, N.: Neuere Erkenntnisse über den Mechanismus der Fibrinolyse unter besonderer Berücksichtigung der Fibrinogen-Elektrophorese. Behringwerk-Mitteilungen 41, 84 (1962).
Herndorn, R. M., J. S. Meyer, J. F. Johnson, and J. Landers: Treatment of cerebrovascular thrombosis with fibrinolysin. Preliminary report. Amer. J. Cardiol. 6, 540 (1960).
Holemans, R., and R. Gross: Influence of blood platelets on fibrinolysis. Thrombos. Diathes. haemorrh. (Stuttg.) 6, 196 (1961).
Howard, F. M.: Effect of Plasmin infusion on canine cerebral infarction. Conference on Thrombolytic Agents p. 231 Chicago, 1960.
Howden, G. D.: The successfull treatment of a case of central retinal vein thrombosis with intravenous fibrinolysin. Canad. med. Ass. J. 81, 382 (1959).
Hörven, J.: The effect of fibrinolysin (plasmin) on blood injected into the anterior chamber of the eye in rabbits. Acta Ophthal. (Kbh.) 39, 44 (1961).
Hume, M.: Thrombolysis of the experimental radioactive pulmonary embolus. Its demonstration with the use of several agents. New Engl. J. Med. 264, 471 (1961).
Hume, M. W., W. L. Glenn, and T. Grillo: Behavior in circulation of radioactive pulmonary embolus and its application to the study of fibrinolytic enzymes. Ann. Surg. 151, 507 (1960).
Jacobssen, K.: Studies on the trypsin and plasmin inhibitors in human blood serum. Scand. J. clin. Lab. Invest. 7 (Supp.), 1955.
Johnson, A. J., A. P. Fletcher, W. R. Mcarthy, and W. S. Tillett: The intravascular use of streptokinase. Ann. N. Y. Acad. Sci. 68, 201 (1957 a).
Johnson, A. J., A. P. Fletcher, W. R. Mcarthy, and W. S. Tillett Effects in patients of intravenous infusions of purified streptokinase preparations. Proc. Soc. exp. Biol. (N. Y.) 94, 254 (1957b).
Johnson, A. J., A. P. Fletcher, W. R. Mcarthy, and W. R. Mcarty: Streptokinase as a thrombolytic agent. Amer. J. Cardiol. 6, 487 (1960).
Johnson, A. J., A. P. Fletcher, W. R. Mcarthy, and J. Newman: Urokinase as a thrombolytic agent in man. IX. Congr. Soc. Europ. hematol. Lissabon 1963.
Johnson, A. J., A. P. Fletcher, W. R. Mcarthy, and W. S. Tillett: The lysis of rabbits of intravascular blood clots by the streptococcal fibrinolytic system (streptokinase). J. exp. Med. 95, 449 (1952).
Johnson, A. J., A. P. Fletcher, W. R. Mcarthy, and C. L. Schneider: The existence of antifibrinolysin activity in platelets. Science 117, 229 (1953).
Jukofsky, S. L.: A new technique in the treatment of hyphema. Amer. J. Ophthal. 34, 1692 (1951).
Jürgens, J.: Erfahrungen in der therapeutischen Fibrinolyse mit dem Streptokinasepräparat der Behring-Werke A.-G. Berhingwerk-Mitteilungen 41, 114 (1962).
Jürgens, J. Erfahrungen in der therapeutischen Fibrinolyse mit SK-und Piasmininfusionen. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 3 ad Vol VII, 163 (1963 a).
Jürgens, J. Persönliche Mitteilung (1963b).
Jürgens, J. Therapeutische Fibrinolyse. Klin. Wschr. 11, 534 U. 539 (1964).
Jürgens, J., U., F. K. Beller: Klinische Methoden der Blutgerinnungsanalyse. Stuttgart: Georg Thieme 1959.
Jung, E. G., U. F. Duckert: Wirkung von Plasmin (Fibrinolysin) auf die Gerinnungsfaktoren. Schweiz. med. Wschr. 44, 1239 (1960).
Kahn, P., A. Stacher U. E. Deutsch: Thrombolytische Therapie mit hochgereinigter Streptokinase. Wien. klin. Wschr. 40, 677 (1961).
Kappert, A.: Experimentelle und klinische Untersuchungen über arterielle Thrombogenese und Fibrinolyse. Basel/Stuttgart: Benno Schwabe & Co. Verlag 1962.
Kaulla, K. N. V.; The extraction of fibrinolytic enzyme from blood. Nature (Lond.) 164, 40 (1949).
Kaulla, K. N. V. Betrachtungen zur postnarkotischen Fibrinolyse. Schweiz. med. Wschr. 77, 313 (1947).
Kaulla, K. N. V. Antikoagulation und Fibrinolyse. Medizinische 5, 1651 (1953).
Kaulla, K. N. V.: Intravenous protein-free pyrogens. A most powerful fibrinolytic agent in man. Circulation 17, 18 (1958).
Kaulla, K. N. V. Urokinase-induced fibrinolysis of human standard clots. Nature (Lond.) 184, 1320 (1959).
Kaulla, K. N. V. Fibrinolysis in man induced by non-enzymatic, non-pyrogenic drugs. Conference on Thrombolytic Agents, p. 94, Chicago 1960.
Kaulla, K. N. V. Chemistry of thrombolysis: human fibrinolytic enzymes, 1963, Springfield/Illinois/US A: Charles C. Thomas, Publisher.
Kaulla, K. N. V., and L. B. Shettles: Relationship between human seminal fluid and the fibrinolytic system. Proc. Soc. exp. Biol. (N. Y.) 83, 692 (1953).
Kaulla, K. N. V., and L. B. Shettles Beitrag zur Kenntnis des proteolytischen Fermentsystems im menschlichen Spermaplasma, Mucus cervialis, Tubarschleimhaut und Liquor folliculi. Klin. Wschr. 32, 468 (1954).
Kaulla, K. N. V., and H. Swan: Clotting deviation in man during cardiac by-pass: fibrinolysis and circulating anticoagulant. J. thorac. Surg. 36, 519 (1958).
Kline, D. L.: The purification and crystallization of plasminogen (Profibrinolysin). J. biol. Chem. 204, 949 (1953).
Kline, D. L. Interaction of streptokinase and plasminogen to form an SK-Plasmin activator of plasminogen. IX. Congr. Soc. Europ. haematol. Lissabon, 1963.
Kline, D. L., and J. B. Fishman: The humoral protease. Ann. N. Y., Acad. Sci. 68, 25 (1957).
Klingleb, M.: Persönliche Mitteilung. 1963.
Kolleb, F.: The development of our knowledge of fibrinolysis. Amer. J. Cardiol. 6, 367 (1960 a).
Kolleb, F. Fibrinolyse. Schweiz. med. Wschr. 90, 1233 (1960b).
Kolmen, S. N., M. M. Guest, and D. R. Celandeb: Evidence for the absorption upon erythrocytes of urokinase and other components of the fibrinolytic system. Arch. Biochem. Biophys. 85, 334 (1959).
Köbtge, P.: The value of streptokinase-induced fibrinolysis in the treatment of acute myocardial infarction. IX. Congr. Soc. Europ. hematol. Lissabon 1963.
Kwaan, H. C., R. Lo, and A. J. S. MFadzean: On the production of plasma fibrinolytic activity within veins. Clin. Sci. 16, 241 (1957).
Kwaan, H. C., R. Lo, and A. J. S. Mfadzean On the lysis of thrombi experimentally produced within veins. Brit. J. Haemat. 4, 51 (1958).
Laei, K.: The polymerization of protein: The action of thrombin on fibrinogen. Arch. Biochem. 32, 317 (1951).
Lassen, M.: The reaction between streptokinase and human plasma. Acta chem. scand. 13, 1332 (1959).
Lassen, M. Effect of streptokinase on human blood. Conference on Thrombolytic Agents, p. 57, Chicago, 1960.
Latallo, A., Z. Budzynski, B. Lipinski, and E. Kowalski: Studies on fibrinogen digestion products. IX. Congr. Soc. Europ. hematol. Lissabon 1963.
Latallo, Z. S., A. P. Fletcher, N. Alkjaersig, and S. Sherry: Influence of PH, ionic strength, neutral ions and thrombin on fibrin polimerization. Amer. J. Physiol. 202, 675, 681 (1962).
Leon, A. G. De, S. Bellet, G. Tsituobis, L. E. Lecks, and H. Sandberg: The fibrinolytic system and use of fibrinolysin in myocardial infarction. Amer. J. Cardiol. 5, 674 (1960).
Lewis, J. H., and J. H. Febguson: Studies on a proteolytic enzyme system of the blood. IV. Activation of Profibrinolysin by serum fibrinolysokinase. Proc. Soc. exp. Biol. (N. Y.) 78, 184 (1951).
Lindeke, H. J., and S. R. Masler: Therapy of retinal vein occlusion. Use of fibrinolysin and anticoagulants. Amer. J. Ophthalm. 51, 456 (1961).
Loo, J. Van De, K. A. Rosenkranz, A. Dbews, and E. Fritze: Combined fibrinolytic anticoagulant treatment of myocardial infarction. IX. Congr. Soc. Europ. hematol. Lissabon, 1963).
Loband, L.: Properties and significance of the fibrin-stabilizing-factor (FSF) In: Progress in Coagulation, p. 238, Stuttgart: Friedrich-Karl Schattauer-Verlag 1962.
Ludwig, H.: Thrombolyse durch Streptokinase. Dtsch. med. Wschr. 23, 1105 (1964).
Mahaley, M. S., W. T. Weaver, B. Woodhall, and W. G. Anlyan: Treatment of experimental carotid emboli by regional extracorporeal perfusion with fibrinolysin. Surg. Forum 12, 392 (1961).
Marin, H. M., M. Steeanini, F. Soardi, and L. Müller: Fibrinolysis. V. The thrombolytic and anticoagulant activity of mold fibrinolysin (Aspergillin 0) in vitro. J. Lab. clin. Med. 58, 47 (1961).
Mabx, R.: Bemerkungen zur klinischen Anwendung der gereinigten Streptokinase (Streptase®). Behringwerk-Mitteilungen 41, 103 (1962).
Mabx, R. Indications of thrombolytic therapy. IX. Congr. Soc. Europ. hematol., Lissabon (1963a).
Marx, R.: Wirkungsweise der Fibrinolytika und Antifibrinolytika. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 3 ad Vol. VII, 27 (1963b).
Marx, R., U. P. Clemente: Kritische Arbeit über quantitative und qualitative Beziehungen fibrinolytisch und antifibrinolytiseh wirkender Substanzen. Dissertation, München 1957.
Marx, R., U. P. Clemente E. Werle U. W. Appel: Zum Problem eines Antidotes in der internen Thrombotherapie mit Fibrinolytica. Blut 5, 367 (1959). Marx, R., U. P. Clemente, U. K. Hennig: Über Verstärkersubstanzen der Antifibrinolysewirkung der Epsilon-Aminocapronsäure (ACS) im Organismus. Proc. 8th Congr. Europ. Soc. Haemat. Wien. Basel: Karger 1962.
Mnicol, G. P.: Thrombolytic thérapie. Proc. roy. Soc. Med. 56, 414 (1963).
Mnicol, G. P., A. S. Douglas, and C. Bayley: Experience with streptokinase infusions. Lancet 1962 a II, 1297.
Mnicol, G. P., A. P. Fletcher, N. Alkjaeesig, and S. Sherry: The absorption, distribution and excretion of epsilon-aminocapric acid following oral or intravenous administration to man. J. Lab. clin. Med. 59, 15 (1962b).
Meneghini, P., e. F. Piccinini: Attivazione fibrinolitica del sangue da acido e da alcool nicotinico. Arch. E. Maragliano Pat. Clin. 14, 69 (1958).
Meyer, J. S., R. M. Heendorn, F. Gotsch, Y. Tazaki, J. W. Nelson, and J. F. Johnson: Therapeutic Thrombolysis: In Cerebral Vascular Diseases, p. 160. Third Conference. New York-London: Grune & Stratton 1961.
Michel, J., Seitz, R.: Problem der sogenannten Netzhautvenenthrombose. Wien. med. Wschr. 8, 180 (1963).
Mogensen, B., V. Laeson, O. Storm, and K. E. Sjølin: Experience from trials with a thrombolytic enzyme. Transactions 7e congrès, Union Internationale de Thérapeutique, Genève, Octobre 1961.
Morgagni, J. B.: The seats and causes of diseases. Vol. III, letter 53, book IV: 185, London 1769.
Moeton, W. R., and W. Turnbull: An unusual case of central retinal vein occlusion, treated successfully with intravenous fibrinolysin. Canad. med. Ass. J. 85, 844 (1961).
Moser, K. M.: Effects of intravenous administration of fibrinolysin (plasmin) in man. Circulation 20, 42 (1959a).
Moser, K. M. Clinical observations in thromboembolic disease treated with fibrinolysin. Angiology 10, 319 (1959b).
Moser, K. M. Therapy with thrombolytic agents. In: Wright/Koller/Streuli: Thrombolytic activity and related phenomena, p. 305. Stuttgart: Friedrich-Karl Schattauer Verlag 1961.
Moser, K. M. G. C. Hajjar, and S. B. Sulavik: Fibrinolytic therapy in acute deep thrombophlebitis: Interim report of a controlled study. Angiology 12, 195 (1961).
Müller, K. H.: Erhöht die thrombolytische Therapie mit Streptokinase die Blutungsgefahr nach operativen Eingriffen? Langenbecks Arch. klin. Chir. 300, 570 (1962).
Müllertz, S.: A plasminogen activator in spontaneously active human blood. Proc. Soc exp. Biol. (N. Y.) 82, 291 (1953).
Müllertz, S. Formation and properties of human and bovine plasmin. Biochem. J. 61, 424 (1955).
Müllertz, S. Chemistry of fibrinolysis, Discussion: Theories of plasminogen activation. Thrombos. Diathes. haemorrh. (Stuttg.) Supp. 1 ad Vol. VI, 142 (1960).
Müllertz, S., and M. Lassen: An activator system in blood indispendable for the formation of plasmin by streptokinase. Proc. Soc. exp. Biol. (N. Y.) 82, 264 (1953).
Nicola, P. DE: The role of indirect fibrinolytic agents in thrombolytic therapy. IX. Congr. Soc. Europ. hematol. Lissabon 1963.
Niewiarowsky, S., et E. Kowalski: Un nouvel anticoagulant dérivé du fibrinogène. Rev. Hémat. 13, 320 (1958).
Nilsson, J. M., S. E. Bjoerkman, and J. Andersson: Clinical experiences with epsilon-aminocaproic acid as an antifibrinolytic agent. Acta med. scand. 170, 487 (1961).
Nilsson, J. M., S. E. Bjoerkman, and B. Olow: Fibrinolysis induced by streptokinase in man. Acta chir. scand. 123, 247 (1962).
Nilsson, J. M., A. Sjoerdsma, and J. Waldenstroem: Antifibrinolytic activity and metabolism of epsilon-aminocaproic acid in man. Lancet I 1960, 1322.
Nolf, P.: Les modifications de la coagulation du sang chez le chien après l’extirpation du fois. Arch. int. Physiol. 3, 1 (1905).
Nolf, P. Contribution à l’étude de la coagulation du sang (5ième mémoire) La Fibrinolyse. Arch. int. Physiol. 6, 306 (1908).
Noeman, P. S.: Studies of the plasmin system. II. Inhibition of plasmin by serum or plasma. J. exper. Med. 108, 53 (1958).
Noeman, P. S., and B. M. Hill: Studies of the plasmin system. III. Physical properties of the two plasmin inhibitors in plasma. J. exp. Med. 108, 639 (1958).
Nydick, J., P. Ruegseggeb, C. Bouvier, R. V. Hutter, R. Abarquez, E. E. Gliffon, and J. S. LaDue: Salvage of heart muscle by fibrinolytic therapy after experimental coronary occlusion. Amer. Heart J. 61, 93 (1961).
Okamoto, S.: Patent specification 770693; London, England, The Patent Office, October 21, 1954, p. 9.
Oliveras, F. E., O. E. Garcia Reyes, F. L. Raffucci, and V. Perez: Fibrinolysin in the treatment of thrombosed arterial prostetic grafts. Experimental study. Amer. J. Surg. 105, 779 (1963).
Perlick, E.: Gerinnungslaboratorium in Klinik und Praxis. Leipzig: VEB Georg Thieme, 1960.
Pezold, F. A.: Persönliche Mitteilung, 1963.
Poliwoda, H., R. Schroeder U. F. Heceneb: Erste Erfahrungen mit der fibrinolytischen Therapie beim akuten Myokardinfarkt. Dtsch. med. Wschr. 5, 218 (1963).
Randolph, W. A.: General Discussion in Conference on thrombolytic agents, p. 221. Chicago 1960.
Ratnoff, O. D.: Fibrinogen and fibrin as substrates for the proteolytic enzyme of plasma. J. clin. Invest. 32, 473 (1953).
Remmert, L. F., and P. P. Cohen: Partial purification and properties of a proteolytic enzyme of human serum. J. biol. Chem. 181, 431 (1949).
Richter, J. H., E. E. Cliffton, S. Epstein, F. Musacchio, A. Nassar, A. G. Favazza, and G. Katabi: Thrombolysin therapy in myocardial infarction. Amer. J. Cardiol. 9, 82 (1962).
Rintelen, F.: Persönliche Mitteilung, 1963.
Ruegsegger, P., J. Kydick, R. Abarques, F. Reichel, E. E. Cliffton, and J. S. Ladue: Effect of fibrinolytic (plasmin) therapy on the physiopathology of myocardial infarction. Amer. J. Cardiol. 6, 519 (1960).
Ruegsegger, P., J. Kydick, R. R. C. Hutter, A. H. Freiman, N. U. Bang, E. E. Cliffton, and J. S. Ladue: Fibrinolytic (plasmin) therapy of experimental coronary thrombi with alteration of the evolution of myocardial infarction. Circulation 19, 7 (1959).
Sandritter, W.: Die Morphologie der Thrombolyse: Verh. 8. Kongr. Europ. Ges. Hämat., Wien 1961.
Sandritter, W. H. D. Bergerhof U. R. Kroger: Morphologische Untersuchungen zur Wirkung des Heparins auf experimentelle Abscheidungsthrombose. Frankf. Z. Path. 65, 343 (1954).
Sandritter, W. M. Huppert U. G. Schlueter: Zur Frage der Fibrinolyse an experimentellen Gerinnungsund Abscheidungsthromben. Klin. Wschr. 36, 651 (1958).
Sawyer, W. D., N. Alkjaersig, A. P. Fletcher, and S. Sherry: A comparison of the fibrinolytic and fibrinogenolytic effects of plasminogen activators and proteolytic enzymes in plasma. Thrombos Diathes. haemorrh. (Stuttg.) 5, 149 (1960).
Sawyer, W. D., N. Alkjaersig, A. P. Fletcher, and S. Sherry Thrombolytic therapy: basic and therapeutic considerations. Arch. intern. Med. 107, 274 (19
Scheerer, R. Seitz, R.: Probleme der sogenannten Netzhautvenenthrombose. Wien med. Wschr. 8, 180 (1963).
Scheie, H. G., B. J. Ashley, and A. Weiner: The treatment of total hyphema with fibrinolysin (plasmin). Arch. Ophthalm. 66, 102 (1961).
Schmidt, H. W.: Kommt es durch Streptokinase zur Thrombolyse ? Dtsch. med. Wschr. 28, 1385 (1963).
Schmidt, H. W. Zur thrombolytischen Therapie mit Streptokinase. Dtsch. med. Wschr. 28, 1407 (1963).
Schmitz, A.: Über die Proteinase des Fibrins. Z. phys. Chem. 224, 89 (1936).
Schmutzler, R.: Unveröffentlichte Resultate (1962).
Schmutzler, R.: Spontanfibrinolysen und Hemmwirkung von Epsilon-Aminocapronsäure und Trasylol. Folia haemat. (Frankfurt) N. F. 8, 33 (1963a).
Schmutzler, R.: Indikationen und praktische Durchführung der thrombolytischen Therapie. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 3 ad VII, 143 (1963b).
Schmutzler, R.: Recent therapeutic aspects of thrombolysis. IX. Congr. Soc. Europ. hematol. Lissabon, (1963 c).
Schmutzler, R.: Neuere Erkenntnisse der therapeutischen Fibrinolyse. Helv. med. Acta 30, 608 (1963 d).
Schmutzler, R., U. E. Beck: Die Wirkung von Epsilon-Aminocapronsäure und Trasylol auf die Fibrinolyse. Schweiz. med. Wschr. 43, 1368 (1962).
Schmutzler, R., U. F. Duckert: Unveröffentlichte Resultate, 1963.
Schmutzler, R., U. F. Koller: The clinical values of fibrinolytic enzymes, results and perspectives of thrombolytic therapy. IX. Congr. Soc. Europ. hematol. Lissabon 1963.
Schultze, H. E., N. Heimburger, K. Heide, H. Haupt, K. Stoeriko, and H. G. Schwick: Preparation and characterization of α1trypsin inhibitor and α2-plasmin inhibitor of human serum. IX. Congr. Soc. Europ. hemat. Lissabon 1963.
Seegers, W. H., R. H. Landaburn, and J. F. Johnson: Thrombin-E as a fibrinolytic enzyme. Science 131, 726 (1960).
Seitz, R.: Probleme der sogenannten Netzhautvenenthrombose. Wien. med. Wschr. 8, 180
Sheffer, A. L., and H. L. Isbrael: Treatment of pulmonary embolism with fibrinolvsin Angiology 10, 292 (1959).
Sherry, S.: The fibrinolytic activity of streptokinase-activated human plasma. J. clin Invest. 33, 1054 (1954).
Sherry, S., and A. P. Fletcher: Proteolytic enzymes: a therapeutic evaluation. Clin. Pharmacol. Ther. 1, 202 (1960).
Sherry, S., and N. Alkjaersig: Fibrinolysis and fibrinolytic activity in man. Physiol. Rev. 39 343 (1959 a).
Sherry, S., R. J. Lindemeyer, A. P. Fletcher, and N. Alkjaresig: Studies on enhanced fibrinolytic activity in man. J. clin. Invest. 38, 810 (1959b).
Sherry, S., R. J. A. Titchener, L. Gottesman, P. Wasserman, and W. Troll: The enzymatic dissolution ot experimental arterial thrombi in the dog by trypsin, chymotrypsin and plasminogen activators. J. clin. Invest. 33, 1303 (1954).
Shulman, N. R.: Studies on the inhibition of proteolytic enzymes by serum. I. The mechanism ot the inhibition of trypsin, plasmin and chymotrypsin by serum using fibrin tagged with I131 as a substrate. J. exp. Med. 95, 571 (1952).
Shulman, S., N. Alkjaersig and S. Sherry: Physiochemical studies on human plasminogen (Profibrinolysin) and plasmin (fibrinolysin). J. biol. Chem. 233, 91 (1958).
Smillie, J. W.: The effect of streptokinase on simulated hyphema. Amer. J. Ophthal. 37, 911
Smyrniotis, F. E., A. P. Fletcher, N. Alkjaersig, and S. Sherry: Urokinase excretion m health and its alteration in certain disease states. Thrombos. Diathes. haemorrh. (Stuttg.) 3, 257 (1959).
Stacher, A.: Persönliche Mitteilung 1961.
Stacher, A., U. J. Böhnel: Die Dosierung der Streptokinase bei fibrinolytischer Therapie. Wien. klin Wschr. 39, 665 (1961).
Stamm, H.: Einführung in die Klinik der Fibrinolyse. Basel/New York: Karger 1962.
Stefanini, M.: Fibrinolysis III. Nutritional and environmental requirements for optimum Production of fibrinolysin from Aspergillus (Aspergillin 0). Proc. Soc. exp. Biol. (N. Y.) 102, 201 (1959).
Stefanini, M., and B. R. Gendal: Clin. Res. 1, 5 (1953).
Steichele, D. F., U. H. J. Herschlein: Zur antifibrinolytischen Wirkung des Trypsin-Kallikrem-Inaktivators. Med. Welt 42, 2175 (1961).
Storm, O., C. J. Amris, V. Larsen U. B. Mogensen: Klinische Erfahrungen mit Plasmin Novo Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 3 ad Vol. VII, 179 (1963).
Stricker, E., U. R. Schmutzler: Erfolgreiche Behandlung eines arteriellen cerebralen Gefäßverschlusses. Schweiz. med. Wschr. 18, 615 (1964).
Thies, H. A.: Persönliche Mitteilung, 1963.
Tillett, W. S., and R. L. Garner: The fibrinolytic activity of hemolytic streptococci. J. exp. Med. 58, 485 (1933).
Tillett, W. S., A. J. Johnson, and W. R. Mcarty: The intravenous infusion of the streptococcal fibrinolytic principle (streptokinase) into patients. J. clin. Invest. 34, 169 (1955).
Todd, A. S.: The histological localisation of fibrinolysin activator. J. Path. Bact. 78, 281 (1959).
Ungar, G., E. Damgaard, and F. P. Hummel: The fibrinolysin-antifibrinolysin-system im serum: mechanism of its endocrine control. Endocrinology 49, 805 (1951)
Verhoeff, F H: Zit. bei SEITZ, R.: Probleme der sogenannten Netzhautvenenthrombose. Wien. med. Wschr. 8, 180 (1963).
Veestraete, M., et A. Amery: Expériences cliniques avec la streptokinase comme agent thrombolytique. Acta cardiol. (Brux.) 18, 235 (1963).
Veestraete, M., et A. Amery and J. Vermylen: The feasibility of adaequate thrombolytic therapy with streptokinase m peripheral arterial occlusions. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 3 ad VII, 211 (1963a).
Veestraete, M., et A. Amery and J. Vermylen Feasibility of adequate thrombolytic therapy with streptokinase in peripheral earterial occlusions. II Changes in peripheral blood and thrombolysis in vivo. Brit. med. J. l963 bI, 15
Villavicencio, J. L., and R. Warren: Experience with the use of human fibrinolvsin. Angiology 10, 263 (1959).
Weiner, M., W. Redisch, and M. Steele: Occurrence of fibrinolytic activity following administration of nicotinic acid. Proc. Soc. exp. Biol. (N. Y.) 98, 755 (1958)
Werle E., L. Maier U. E. Ringelmann: Hemmung von Proteinasen durch Kallikrein-Inaktivatoren. Naturwissenschaften 39, 328 (1952).
Whisnant J. P., C. H. Millikan, and R. G. Siekert: Cerebral infarction and fibrinolytic agent. Conference on Thrombolytic Agents, p. 235, Chicago 1960.
Whitman, W. L., TH. Shohl, and W. F. Barker: Prevention of arterial thrombosis following experimental endarteriectomy with plasmin (fibrinolysin). Ann. Surg. 153, 533 (1961).
Widmer, L.: Periphere Athérosclérose. Schweiz. med. Wschr. 93, 1583 (1963).
Wildman, C. J.: Intramuscular trypsin in treatment of chronic thrombophlebitis. Angiology 6, 473 (1955).
Wilson, W. L., and G. Fostiropoulos: Observations on the use of nicotinic acid to induce in vivo fibrinolytic activity. Amer. J. med. Sci. 238, 591 (1959).
Winckelmann, G., V. Hiemeyer, H. Weissleder U. W. Schoop: Die thrombolytische Behandlung mit Streptokinase bei akuten arteriellen Verschlußkrankheiten. Dtsch. med. Wschr. 48, 2331 (1963).
Witte, S.: Klinische Erfahrungen über die Dosierung der fibrinolytischen Therapie. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 3 ad VII, 189 (1963).
Zimmermann, W.: Zit. aus MacFarlane and Biggs: Fibrinolysis. Its mechanism and significance. Blood 3, 1167 (1948).
Zintz, E., U. R. Schmutzler: Unveröffentlichte Resultate 1963.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1965 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Schmutzler, R., Koller, F. (1965). Die Thrombolyse-Therapie. In: Heilmeyer, L., Schoen, R., Prader, A. (eds) Ergebnisse der Inneren Medizin und Kinderheilkunde. Ergebnisse der Inneren Medizin und Kinderheilkunde, vol 22. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-94910-4_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-94910-4_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-94911-1
Online ISBN: 978-3-642-94910-4
eBook Packages: Springer Book Archive